|
Navarro-Zaragoza J, Núñez C, Laorden ML, Milanés MV. Effects of corticotropin-releasing factor receptor-1 antagonists on the brain stress system responses to morphine withdrawal. Mol Pharmacol. 2010 May;77(5):864-73. doi: 10.1124/mol.109.062463. Epub 2010 Feb 16. PubMed PMID: 20159948.
AÑO: 2010; IF: 4.436
|
20159948
|
Navarro-Zaragoza J, Núñez C, Ruiz-Medina J, Laorden ML, Valverde O, Milanés MV. CRF? mediates the increased noradrenergic activity in the hypothalamic paraventricular nucleus and the negative state of morphine withdrawal in rats. Br J Pharmacol. 2011 Feb;162(4):851-62. doi: 10.1111/j.1476-5381.2010.01090.x. PubMed PMID: 20973778; PubMed Central PMCID: PMC3042196.
AÑO: 2011; IF: 8.739
|
|
Almela P, Navarro-Zaragoza J, García-Carmona JA, Mora L, Hidalgo J, Milanés
MV, Laorden ML. Role of corticotropin-releasing factor (CRF) receptor-1 on the
catecholaminergic response to morphine withdrawal in the nucleus accumbens (NAc).
PLoS One. 2012;7(10):e47089. doi: 10.1371/journal.pone.0047089. Epub 2012 Oct 10.
Erratum in: PLoS One. 2013;8(5).
doi:10.1371/annotation/3708ead6-a61a-48b4-aca4-c45b3b7dd292. PubMed PMID:
23071721; PubMed Central PMCID: PMC3468529
AÑO: 2012; IF: 3.73
|
|
Navarro-Zaragoza J, Hidalgo JM, Laorden ML, Milanés MV. Glucocorticoid receptors participate in the opiate withdrawal-induced stimulation of rats NTS noradrenergic activity and in the somatic signs of morphine withdrawal. Br J Pharmacol. 2012 Aug;166(7):2136-47. doi: 10.1111/j.1476-5381.2012.01918.x. PubMed PMID: 22364199; PubMed Central PMCID: PMC3402777.
AÑO: 2012; IF: 5.067
|
|
Navarro-Zaragoza J, Martínez-Laorden E, Mora L, Hidalgo J, Milanés MV, Laorden ML. Cardiac adverse effects of naloxone-precipitated morphine withdrawal on right ventricle: role of corticotropin-releasing factor (CRF) 1 receptor. Toxicol Appl Pharmacol. 2014 Feb 15;275(1):28-35. doi: 10.1016/j.taap.2013.12.021. PubMed PMID: 24398105.
AÑO: 2014; IF: 3.347
|